In contrast, the engineered approach of anchoring ADA1 to T cells through a tumor-activated scFv (ADA1-scFv(CD3)) provides several distinct advantages: enhanced tumor specificity, dramatically increased local binding affinity, and the ability to recruit and activate endogenous T cells via bystander effects. This evidence concerns the gene ADA and neoplasm.